Do gabapentin or pregabalin directly modulate the µ receptor?
Background Pregabalin and gabapentin improve neuropathic pain symptoms but there are emerging concerns regarding their misuse. This is more pronounced among patients with substance use disorder, particularly involving opioids. Co-ingestion of gabapentinoids with opioids is increasingly identified in...
Hauptverfasser: | Preeti Manandhar, Bridin Patricia Murnion, Natasha L. Grimsey, Mark Connor, Marina Santiago |
---|---|
Format: | Artikel |
Sprache: | English |
Veröffentlicht: |
PeerJ Inc.
2021-04-01
|
Schriftenreihe: | PeerJ |
Schlagworte: | |
Online Zugang: | https://peerj.com/articles/11175.pdf |
Ähnliche Einträge
Ähnliche Einträge
-
Gabapentin and pregabalin exposures reported to United States poison centers, 2012–2022
von: Emily J.R. Carter, et al.
Veröffentlicht: (2024-11-01) -
A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder
von: Qin Xiang Ng, et al.
Veröffentlicht: (2021-08-01) -
Efficacy and safety of pregabalin and gabapentin in spinal stenosis: a systematic review and meta-analysis
von: Telmo Martínez, et al.
Veröffentlicht: (2023-11-01) -
Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
von: Payal H. Desai, PharmD, BCCCP, et al.
Veröffentlicht: (2021-07-01) -
Gabapentin and Pregabalin in chronic neuropathic pain: cost efficacy evaluation
von: Paolo Marchettini, et al.
Veröffentlicht: (2005-05-01)